title: Leucocyte cathepsin K affects atherosclerotic lesion composition and bone mineral density in low-density lipoprotein receptor deficient mice.
abstract: OBJECTIVE
  Cathepsin K (CatK), an established drug target for osteoporosis, has been reported to be upregulated in atherosclerotic lesions. Due to its proteolytic activity, CatK may influence the atherosclerotic lesion composition and stability. In this study, we investigated the potential role of leucocyte CatK in atherosclerotic plaque remodelling.
  
  
  RESULTS
  To assess the biological role of leucocyte CatK, we used the technique of bone marrow transplantation to selectively disrupt CatK in the haematopoietic system. Total bone marrow progenitor cells from CatK(+/+), CatK(+/-), and CatK(-/-) mice were transplanted into X-ray irradiated low-density lipoprotein receptor knockout (LDLr(-/-)) mice. The selective silencing of leucocyte CatK resulted in phenotypic changes in bone formation with an increased total bone mineral density in the CatK(-/-) chimeras and an effect of gene dosage. The absence of leucocyte CatK resulted in dramatically decreased collagen and increased macrophage content of the atherosclerotic lesions while lesion size was not affected. The atherosclerotic lesions also demonstrated less elastic lamina fragmentation and a significant increase in the apoptotic and necrotic area in plaques of mice transplanted with CatK(-/-) bone marrow.
  
  
  CONCLUSIONS
  Leucocyte CatK is an important determinant of atherosclerotic plaque composition, vulnerability, and bone remodelling, rendering CatK an attractive target for pharmaceutical modulation in atherosclerosis and osteoporosis.
authors.affiliation: Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research , Gorlaeus Laboratories, Leiden University, Einsteinweg 55, 2333CC Leiden, The Netherlands.
authors.forename: Jian
authors.initials: J
authors.lastname: Guo
authors.forename: Ilze
authors.initials: I
authors.lastname: Bot
authors.forename: Ramon
authors.initials: R
authors.lastname: de Nooijer
authors.forename: Sandra J
authors.initials: SJ
authors.lastname: Hoffman
authors.forename: George B
authors.initials: GB
authors.lastname: Stroup
authors.forename: Erik A L
authors.initials: EA
authors.lastname: Biessen
authors.forename: G Martin
authors.initials: GM
authors.lastname: Benson
authors.forename: Pieter H E
authors.initials: PH
authors.lastname: Groot
authors.forename: Miranda
authors.initials: M
authors.lastname: Van Eck
authors.forename: Theo J C
authors.initials: TJ
authors.lastname: Van Berkel
mesh_terms: D000818:Animals; D001057:Apolipoproteins E / Q000502:physiology; D050197:Atherosclerosis / Q000209:etiology* / Q000378:metabolism; D015519:Bone Density; D016723:Bone Remodeling; D056657:Cathepsin K; D002403:Cathepsins / Q000502:physiology*; D003094:Collagen / Q000378:metabolism; D005260:Female; D007962:Leukocytes / Q000201:enzymology*; D008264:Macrophages / Q000502:physiology; D051379:Mice; D011973:Receptors, LDL / Q000502:physiology*
chemical_list: D001057:Apolipoproteins E; D011973:Receptors, LDL; D003094:Collagen; D002403:Cathepsins; D056657:Cathepsin K; C534132:Ctsk protein, mouse